The very first placebo-controlled clinical trial affirming the antipsychotic properties of CBD found it has “beneficial effects” in patients with schizophrenia and could potentially be a new class of treatment for the disorder.
The findings are consistent with other studies, e.g. a robust clinical trial found CBD was as effective in treating acute psychotic symptoms as the antipsychotic amisulpride. Patients treated with CBD experienced minimal adverse effects, including weight gain.
Schizophrenia patients treated with CBD experienced lower levels of psychotic symptoms and were much more likely to be rated as “improved” and not as “severely unwell” after just six weeks of treatment.
Another clinical trial testing CBD as a treatment for psychosis is now underway, led by medical researchers at King’s College London.
Renowned American psychiatry professor at Mount Sinai School of Medicine and member of the AMERICAN ACADEMY OF MEDICINE, Dr. Yasmin Hurd, told the American Journal of Psychiatry (March 2018) that the clinical trial led by King’s College London found that: